These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1052 related articles for article (PubMed ID: 21147110)

  • 1. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
    Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARĪ± pathways.
    Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
    J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [De novo lipogenesis: role in hepatocellular carcinoma].
    Calvisi DF
    Pathologe; 2011 Nov; 32 Suppl 2():174-80. PubMed ID: 21931995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.
    Bai PS; Xia N; Sun H; Kong Y
    J Cell Mol Med; 2017 Nov; 21(11):3023-3043. PubMed ID: 28557334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
    Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
    Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
    Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
    Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
    Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
    Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
    Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt and mTORC1 have different roles during liver tumorigenesis in mice.
    Kenerson HL; Yeh MM; Kazami M; Jiang X; Riehle KJ; McIntyre RL; Park JO; Kwon S; Campbell JS; Yeung RS
    Gastroenterology; 2013 May; 144(5):1055-65. PubMed ID: 23376645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
    Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.
    Ricoult SJ; Yecies JL; Ben-Sahra I; Manning BD
    Oncogene; 2016 Mar; 35(10):1250-60. PubMed ID: 26028026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
    Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
    J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
    Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
    Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638.
    Ni W; Lin S; Bian S; Zheng W; Qu L; Fan Y; Lu C; Xiao M; Zhou P
    Cell Death Dis; 2020 Oct; 11(10):843. PubMed ID: 33040080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
    Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
    Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.
    Yecies JL; Zhang HH; Menon S; Liu S; Yecies D; Lipovsky AI; Gorgun C; Kwiatkowski DJ; Hotamisligil GS; Lee CH; Manning BD
    Cell Metab; 2011 Jul; 14(1):21-32. PubMed ID: 21723501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.